A Phase 3 interventional study of Technosphere® Insulin Inhalation Powder and 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin) in Diabetes Type 2, sponsored by Mannkind Corporation. Completed at 151 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-10-16.
Sponsored by Mannkind Corporation · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.
Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment, is one of 10 that started in 2006, is one of 25 in phase 3, and was the 2nd registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 26 · Phase 4 7
First in 1999; this study’s year is marked. 10 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 677 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 129 across the 49 interventional studies. Of the 46 that completed or were terminated, 11 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 49 have an industry lead sponsor. The 10 most frequent:
Mannkind Corporation is the lead sponsor of 57 studies on the registry; 3 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
23 studies in Diabetes Mellitus, Type 2 by Mannkind Corporation: none open now, none under way, none of them phase 3. Of 22 finished, 10 (45%) have results posted.
Among the 23 studies in Diabetes Mellitus, Type 2 by Mannkind Corporation, this one is the 2nd largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2006, is one of 9 in phase 3, and was the 1st registered.
Mannkind Corporation’s Diabetes Mellitus, Type 2 studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Mannkind Corporation’s 23 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this 13 month study (12 month treatment period and 1 month follow-up period) is to determine whether inhaled insulin is safe and effective in the treatment of type 2 diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Technosphere® Insulin Inhalation Powder + insulin glargine
Drug: Technosphere® Insulin Inhalation Powder
70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
Drug: 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
Inhalation, 15U/30U
BPR 70/30, which is a premix of intermediate acting and rapid acting insulin given sc
Change From Baseline in HbA1c to Week 52
Time frame: Baseline to Week 52
Change From Baseline in Weight to Week 52
Time frame: Baseline to Week 52
Change From Baseline in Fasting Plasma Glucose to Week 52
Time frame: Baseline to Week 52
Number of Subjects Achieving Week 52 HbA1c Levels Less Than or Equal to 7.0%
Time frame: Week 52
Incidence of Total Hypoglycemia
Defined as hypoglycemic symptoms that are relieved with carbohydrate intake or blood glucose measurement \<= 63 mg/dL, regardless of symptoms.
Time frame: 52 Weeks
Incidence of Severe Hypoglycemia
Severe hypoglycemia occurs when all 3 of the following occur simultaneously: * Subject requires the assistance of another person; * Subject exhibits at least 1 cognitive neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, seizure, loss of consciousness); * Measured BG is ≤ 49 mg/dL (2.7 mmol/L), or, in the absence of a BG measurement, clinical symptoms are reversed by oral carbohydrates, sc glucagon or intravenous glucose administration; OR, * Measured BG is ≤ 36 mg/dL (2.0 mmol/L) with or without symptoms.
Time frame: 52 Weeks
Total Hypoglycemia Event Rate
Number of Hypoglycemic Events/Total Subject Exposure Time (in months)
Time frame: 52 Weeks
Severe Hypoglycemia Event Rate
Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)
Time frame: 52 Weeks
First subject enrolled Feb. 23, 2006 Multi-national trial conducted in US, Canada, Mexico, Brazil, Argentina, Chile, Spain, UK, Poland, Russia
| Milestone | TI + Insulin Glargine | BPR 70/30 |
|---|---|---|
| Started | 334 | 343 |
| Completed | 216 | 246 |
| Not completed | 118 | 97 |
| Withdrew: Adverse event | 29 | 12 |
| Withdrew: Lost to follow-up | 6 | 22 |
| Withdrew: Physician decision | 5 | 8 |
| Withdrew: Protocol violation | 6 | 3 |
| Withdrew: Withdrawal by subject | 50 | 32 |
| Withdrew: Various | 7 | 7 |
| Withdrew: Randomized but not dosed | 11 | 12 |
| Withdrew: Death | 4 | 1 |
| percent | TI + Insulin Glargine | BPR 70/30 |
|---|---|---|
| Change From Baseline in HbA1c to Week 52 | -0.59 ± 0.063 | -0.71 ± 0.061 |
| kilogram | TI + Insulin Glargine | BPR 70/30 |
|---|---|---|
| Change From Baseline in Weight to Week 52 | 0.9 ± 0.32 | 2.5 ± 0.29 |
| milligrams per deciliter | TI + Insulin Glargine | BPR 70/30 |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose to Week 52 | -35.7 ± 4.61 | -17.9 ± 4.21 |
| participants | TI + Insulin Glargine | BPR 70/30 |
|---|---|---|
| Number of Subjects Achieving Week 52 HbA1c Levels Less Than or Equal to 7.0% | 47 | 65 |
Defined as hypoglycemic symptoms that are relieved with carbohydrate intake or blood glucose measurement \<= 63 mg/dL, regardless of symptoms.
| percentage of participants | TI + Insulin Glargine | BPR 70/30 |
|---|---|---|
| Incidence of Total Hypoglycemia | 47.99 | 68.58 |
Severe hypoglycemia occurs when all 3 of the following occur simultaneously: * Subject requires the assistance of another person; * Subject exhibits at least 1 cognitive neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, seizure, loss of consciousness); * Measured BG is ≤ 49 mg/dL (2.7 mmol/L), or, in the absence of a BG measurement, clinical symptoms are reversed by oral carbohydrates, sc glucagon or intravenous glucose administration; OR, * Measured BG is ≤ 36 mg/dL (2.0 mmol/L) with or without symptoms.
| percentage of participants | TI + Insulin Glargine | BPR 70/30 |
|---|---|---|
| Incidence of Severe Hypoglycemia | 4.33 | 9.97 |
Number of Hypoglycemic Events/Total Subject Exposure Time (in months)
| Number of events/subject-month | TI + Insulin Glargine | BPR 70/30 |
|---|---|---|
| Total Hypoglycemia Event Rate | 0.41 | 0.61 |
Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)
| Number of events/100 subject-months | TI + Insulin Glargine | BPR 70/30 |
|---|---|---|
| Severe Hypoglycemia Event Rate | 0.73 | 2.20 |
Collected over From first dose to 30 days after last dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TI + Insulin Glargine | — | 37/323 (11.5%) | 225/323 (69.7%) |
| BPR 70/30 | — | 31/331 (9.4%) | 251/331 (75.8%) |
| Event | TI + Insulin Glargine | BPR 70/30 |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 3/323 | 6/331 |
| Loss of consciousnessNervous system disorders | 1/323 | 3/331 |
| Atrial fibrillationCardiac disorders | 2/323 | 1/331 |
| Coronary artery diseaseCardiac disorders | 2/323 | 0/331 |
| DizzinessNervous system disorders | 2/323 | 0/331 |
| Angina pectorisCardiac disorders | 0/323 | 2/331 |
| Coronary artery insufficiencyCardiac disorders | 0/323 | 2/331 |
| CholecystitisHepatobiliary disorders | 0/323 | 2/331 |
| CholelithiasisHepatobiliary disorders | 0/323 | 2/331 |
| AppendicitisInfections and infestations | 0/323 | 2/331 |
| Event | TI + Insulin Glargine | BPR 70/30 |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 155/323 | 228/331 |
| CoughRespiratory, thoracic and mediastinal disorders | 106/323 | 20/331 |
| Upper respiratory tract infectionInfections and infestations | 39/323 | 24/331 |
| NasopharyngitisInfections and infestations | 30/323 | 28/331 |
| Urinary tract infectionInfections and infestations | 10/323 | 21/331 |
| InfluenzaInfections and infestations | 18/323 | 18/331 |
| HeadacheNervous system disorders | 18/323 | 12/331 |
Safety population (23 Subjects randomized but never dosed are not included).
| Age, Continuous(years) | TI + Insulin Glargine | BPR 70/30 | Total |
|---|---|---|---|
| Mean | 55.9 ± 10.68 | 55.9 ± 9.91 | 55.9 ± 10.29 |
| Sex: Female, Male(Participants) | TI + Insulin Glargine | BPR 70/30 | Total |
|---|---|---|---|
| Female | 160 | 185 | 345 |
| Male | 163 | 146 | 309 |
| Fasting Plasma Glucose (FPG)(milligrams per deciliter) | TI + Insulin Glargine | BPR 70/30 | Total |
|---|---|---|---|
| Mean | 171.8 ± 68.53 | 176.2 ± 67.15 | 174 ± 67.82 |
| HbA1c(percentage) | TI + Insulin Glargine | BPR 70/30 | Total |
|---|---|---|---|
| Mean | 8.7 ± 1.14 | 8.7 ± 1.10 | 8.7 ± 1.12 |
| Weight(kilogram) | TI + Insulin Glargine | BPR 70/30 | Total |
|---|---|---|---|
| Mean | 88.1 ± 17.33 | 85.7 ± 18.07 | 86.9 ± 17.74 |
Showing the first 100 of 151 sites across 10 countries. Choose a country and city above to see the rest.
The record gives a start of Feb 2006, a primary completion of Aug 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 6 years 2 months after primary completion. A results delay was requested in Jun 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin, Regular, Human